Ocular Gene Therapy for Choroideremia: Clinical Trials and Future Perspectives
Overview
Authors
Affiliations
Introduction: Gene therapy offers the potential for targeted replacement of single gene defects in inherited retinal degenerations.
Areas Covered: Choroideremia is an X-linked blinding retinal disease resulting from deficiency of the gene product, REP1. The disease represents an ideal target for retinal gene therapy, as it is readily diagnosed in the clinic, relatively homogenous in phenotype and slow progressing, thereby providing a wide therapeutic window for intervention. Ongoing clinical trials of retinal gene therapy for choroideremia using an adeno-associated viral vector have demonstrated safety and early efficacy. We review the clinical characteristics of the disease with a view to interpreting the findings of gene therapy clinical trials and discuss future directions.
Expert Commentary: Choroideremia gene therapy has so far demonstrated good safety profile and early functional visual acuity gains in a proportion of trial participants, which appear to be sustained.
Ocular Gene Therapy: An Overview of Viral Vectors, Immune Responses, and Future Directions.
Banou L, Sarrafpour S, Teng C, Liu J Yale J Biol Med. 2024; 97(4):491-503.
PMID: 39703610 PMC: 11650918. DOI: 10.59249/HWID7537.
Wang J, Zhan W, Gallagher T, Gao G Mol Ther. 2024; 32(12):4185-4207.
PMID: 39489915 PMC: 11638839. DOI: 10.1016/j.ymthe.2024.10.017.
Li Y, Yang R, Li Y, Hsu C, Jenny L, Kong Y JCI Insight. 2024; 9(16).
PMID: 39171529 PMC: 11343589. DOI: 10.1172/jci.insight.177231.
Shen C, You B, Chen Y, Li Y, Li W, Wei W Mol Vis. 2022; 28:96-113.
PMID: 35814500 PMC: 9239900.
Tropism of AAV Vectors in Photoreceptor-Like Cells of Human iPSC-Derived Retinal Organoids.
McClements M, Steward H, Atkin W, Goode E, Gandara C, Chichagova V Transl Vis Sci Technol. 2022; 11(4):3.
PMID: 35377942 PMC: 8994202. DOI: 10.1167/tvst.11.4.3.